IS8340A
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydroisoindol-2-yl)-piperidine-2,6-dione
Abstract
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.
Term
Term ended
Projected expiry passed 7 March 2026, 0.6 years ago.
- Priority
- Filed
- Projected expiry
- Today
28 claims: 14 independent, 14 dependent
- 1Demands Kröfur What's required:Það sem krafist er: 1. Kristallað 3-(4-amínó-l-oxó-l ,3-díhýdró-ísóindól-2-ýl)-piperidín-2,6-díon sem hefur bylgjubeygjumynstur röntgengeisla á duftformi sem samanstendur af toppi við um það bil 17.5 gráður 20. A crystalline 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidine-2,6-dione having a powder diffraction X-ray powder ray powder consisting of a peak at about 17.5 degrees 20.
- 4Kristallað 3-(4-amínó-l-oxó-l,3-díhýdró-ísóindól-2-ýl)-piperidín-2,6-díon sem hefur bylgjubeygjumynstur röntgengeisla á duftformi sem samanstendur af toppi við um það bil 27 gráður 20. A crystalline 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidine-2,6-dione having a powder diffraction waveform powdered x-ray powder consisting of a peak at about 27 degrees 20.
- 7Kristallað 3-(4-amínó-l-oxó-l,3-díhýdró-ísóindól-2-ýl)-piperidín-2,6-díon sem hefur bylgjubeygjumynstur röntgengeisla á duftformi sem samanstendur af toppi við um það bil 25 gráður 20. A crystalline 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidine-2,6-dione having a powder diffusion x-ray powder diffraction powder consisting of a peak at about 25 degrees 20. Patice Law Firm / E-428-06 / 130606 Patice Law Firm/E-428-06/130606 5, 06 ,. ® 5, 06,. ®
- 10Kristallað 3-(4-amínó-l-oxó-l,3-díhýdró-ísóindól-2-ýl)-piperidín-2,6-díon sem hefur bylgjubeygjumynstur röntgengeisla á duftformi sem samanstendur af toppi við um það bil 28 gráður 20. A crystalline 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidine-2,6-dione having a powdery powder diffraction waveform powder consisting of a peak at about 28 degrees 20.
- 13Crystalline 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidine-2,6-dione having a powdery powder diffraction waveform powder consisting of a peak at about 20 degrees 2θ. 13. Kristallað 3-(4-amínó-l-oxó-l,3-díhýdró-ísóindól-2-ýl)-piperidín-2,6-díon sem hefur bylgjubeygjumynstur röntgengeisla á duftformi sem samanstendur af toppi við um það bil 20 gráður 2θ.
- 16Crystalline 3- (4-amino-10-oxo-1,3-dihydro-isomdol-2-yl) -piperidine-2,6-dione having a powdery powder diffraction waveform powder consisting of a peak at about 19 degrees 2θ. 16. Kristallað 3-(4-amínó-lOxó-l,3-díhýdró-ísómdól-2-ýl)-piperidín-2,6-díon sem hefur bylgjubeygjumynstur röntgengeisla á duftformi sem samanstendur af toppi við um það bil 19 gráður 2θ.
- 17Hið kristallaða 3 -(4-amino-1 -oxo-1, 17. The crystalline 3- (4-amino-1-oxo-1, 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidine-2,6-dione according to claim 16, wherein the pattern additionally comprises peaks of about 19.5 and 25 degrees 20 3-(4-ammó-l-oxó-l,3-díhýdró-ísóindól-2-ýl)-piperidm-2,6-díon samkvæmt kröfu 16, þar sem mynstrið auk þess samanstendur af toppum við um það bil 19.5 og 25 gráður 20..
- 19A crystalline 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidine-2,6-dione having a powder diffusion x-ray powder ray powder consisting of a peak at about 23 degrees 2θ. 19. Kristallað 3-(4-amínó-l-oxó-l,3-díhýdró-ísóindól-2-ýl)-piperidín-2,6-díon sem hefur bylgjubeygjumynstur röntgengeisla á duftformi sem samanstendur af toppi við um það bil 23 gráður 2θ.
- 21Crystalline 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidine-2,6-dione having a powder-ray diffraction x-ray powder comprising a peak at about 15 degrees 20 .. 21. Kristallað 3-(4-amínó-l-oxó-1,3-díhýdró-ísóindól-2-ýl)-piperidín-2,6-díon sem hefur bylgjubeygjumynstur röntgengeisla á duftformi sem samanstendur af toppi við um það bil 15 gráður 20..
- 23Hið kristallaða 3-(4-amínó-l-oxó“l,3-díhýdró-ísóindól-2-ýl)-piperidín-2,6-díon samkvæmt kröfu 1,4,7,10,13,16,19 eða 21, sem er í aðalatriðum hreint. 23. The crystalline 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidine-2,6-dione according to claims 1,4,7,10,13,16,19 or 21, which is essentially pure. Patice Law Firm / E-428-06 / 130606 ι 4 ϋ 1 5. 06. 06 Patice Law Firm/E-428-06/130606 ι 4 ϋ 1 5. 06. 06
- 24Blanda hiðs kristallaða 24. Mix that crystalline 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidine-2,6-dione according to claim 4.5 or 6 and the crystal according to claim 13, 14 or 15. 3-(4-amínó-l-oxó-l,3-díhýdró-ísóindól-2-ýl)-piperidín-2,6-díons samkvæmt kröfu 4,5 eða 6 og kristallinn samkvæmt kröfu 13,14 eða 15.
- 25A composition comprising uncrystallized 25. Samsetning sem samanstendur af ókristölluðu 3- (4-amino-1-oxo-1,3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidine-2,6-dione and crystalline 3-(4-amínó-l-oxó-l,3-(4-arnínó-l-oxó-l,3-díhýdró-ísóindól-2-ýl)-pipertdín-2,6-díon og kristölluðu 3- (4-amino-1-oxo-1,3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidine-2,6-dione according to claim 4, 7 , 10, 13, 16, 19 or 21. 3-(4-amínó-l-oxó-1,3-(4-amínó-l-oxó-l ,3 -díhýdró-í sóindól-2-ýl)-piperidín-2,6-díon samkvæmt kröfu 4, 7,10,13,16,19 eða 21.
- 26Samsetningin samkvæmt krofu 25, sem samanstendur af meira en 50 prósent miðað við þyngd af kristölluðu 26. The composition according to Crocus 25, comprising more than 50 percent by weight of crystalline 3- (4-amino-l-oxo-3- (4-amino-l-oxo-l, 3-dihydro-isoindol-2-yl) -piperidine-2,6-dione. 3-(4-amínó-l-oxó-l,3-(4-amínó-l-oxó-l,3-díhýdró-ísóindól-2-ýl)-piperidín-2,6-díon.
- 27A pharmaceutical composition consisting of crystalline 27. Lyij asamsetning sem samanstendur af kristölluðu 3- (4-amino-1-oxo-1,3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidine-2,6-dione according to claim 1, 7,10,13,16,19 or 21 and a pharmaceutically acceptable carrier. 3-(4-amínó-l-oxó-l,3-(4-amínó-l-oxó-l,3-díhýdró-ísóindól-2-ýl)-piperidín-2,6-díon samkvæmt kröfu 1, 4, 7,10,13,16,19 eða 21 og lyfjafræðilega viðunandi burðarefni.
Independent claims14
539 members in 41 offices
Priority claims7
| Document | Office | Kind | Date |
|---|---|---|---|
| 49972303 | United States of America | P | |
| 49972303 | United States of America | P | |
| 2004028736 | United States of America | W | |
| 2004028736 | United States of America | W | |
| PCTUS2004028736 | – | – | – |
| US20030499723P | – | – | – |
| WO2004US28736 | – | – | – |
Members539
| Document | Office | Kind | |
|---|---|---|---|
| CA2476983A1 | Canada | A1 | |
| CA2486141A1 | Canada | A1 | |
| CA2672000A1 | Canada | A1 | |
| CA2727824A1 | Canada | A1 | |
| CA2727830A1 | Canada | A1 | |
| CA2752122A1 | Canada | A1 | |
| CA2752124A1 | Canada | A1 | |
| CA2752127A1 | Canada | A1 | |
| CA2752140A1 | Canada | A1 | |
| CA2794060A1 | Canada | A1 | |
| CA2794297A1 | Canada | A1 | |
| CA2855306A1 | Canada | A1 | |
| CA2855359A1 | Canada | A1 | |
| WO03097040A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO03097052A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU2003234624A1 | Australia | A1 | |
| AU2003234626A1 | Australia | A1 | |
| AU2003234626C1 | Australia | C1 | |
| WO03097052A3 | World Intellectual Property Organization (WIPO) | A3 | |
| US2004029832A1 | United States of America | A1 | |
| CA2505128A1 | Canada | A1 | |
| CA2505131A1 | Canada | A1 | |
| WO2004043377A2 | World Intellectual Property Organization (WIPO) | A2 | |
| WO2004043378A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU2003290651A1 | Australia | A1 | |
| AU2003290652A1 | Australia | A1 | |
| WO2004043377A3 | World Intellectual Property Organization (WIPO) | A3 | |
| WO2004043378A3 | World Intellectual Property Organization (WIPO) | A3 | |
| AU2004240548A1 | Australia | A1 | |
| CA2525557A1 | Canada | A1 | |
| WO2004103274A2 | World Intellectual Property Organization (WIPO) | A2 | |
| TW200500355A | Taiwan Province of China | A | |
| TW200501945A | Taiwan Province of China | A | |
| KR20050010812A | Republic of Korea | A | |
| KR20050010815A | Republic of Korea | A | |
| NO20055976L | Norway | L | |
| MXPA04011310A | Mexico | A | |
| MXPA04011311A | Mexico | A | |
| EP1505973A2 | European Patent Office (EPO) | A2 | |
| WO2004103274A3 | World Intellectual Property Organization (WIPO) | A3 | |
| AU2004270211A1 | Australia | A1 | |
| CA2537092A1 | Canada | A1 | |
| CA2687924A1 | Canada | A1 | |
| CA2687927A1 | Canada | A1 | |
| CA2688694A1 | Canada | A1 | |
| CA2688695A1 | Canada | A1 | |
| CA2688708A1 | Canada | A1 | |
| CA2688709A1 | Canada | A1 | |
| CA2741412A1 | Canada | A1 | |
| CA2741575A1 | Canada | A1 | |
| WO2005023192A2 | World Intellectual Property Organization (WIPO) | A2 | |
| US2005096351A1 | United States of America | A1 | |
| KR20050072801A | Republic of Korea | A | |
| KR20050072802A | Republic of Korea | A | |
| EP1556033A1 | European Patent Office (EPO) | A1 | |
| MXPA05004734A | Mexico | A | |
| US2005176681A1 | United States of America | A1 | |
| HK1072180A1 | Hong Kong, China | A1 | |
| EP1567154A2 | European Patent Office (EPO) | A2 | |
| EP1567158A2 | European Patent Office (EPO) | A2 | |
| BR0316050A | Brazil | A | |
| CN1668296A | China | A | |
| BR0316057A | Brazil | A | |
| WO2005023192A3 | World Intellectual Property Organization (WIPO) | A3 | |
| MXPA05004780A | Mexico | A | |
| JP2005530780A | Japan | A | |
| JP2005530784A | Japan | A | |
| US2005234017A1 | United States of America | A1 | |
| IS8127A | Iceland | A | |
| CN1697655A | China | A | |
| IL165254D0 | Israel | D0 | |
| IL165258A0 | Israel | A0 | |
| IL165258D0 | Israel | D0 | |
| KR20060012618A | Republic of Korea | A | |
| US2006030594A1 | United States of America | A1 | |
| CN1735412A | China | A | |
| CN1735415A | China | A | |
| US2006035955A1 | United States of America | A1 | |
| MXPA05012155A | Mexico | A | |
| IS8340AThis record | Iceland | A | |
| AU2003234626B2 | Australia | B2 | |
| JP2006508131A | Japan | A | |
| AR047994A1 | Argentina | A1 | |
| EP1635826A2 | European Patent Office (EPO) | A2 | |
| CR8146A | Costa Rica | A | |
| US2006069065A1 | United States of America | A1 | |
| IL171960A0 | Israel | A0 | |
| IL171960D0 | Israel | D0 | |
| PE20060284A1 | Peru | A1 | |
| AP2006003558A0 | African Regional Intellectual Property Organization (ARIPO) | A0 | |
| JP2006514689A | Japan | A | |
| EP1505973A4 | European Patent Office (EPO) | A4 | |
| EP1567158A4 | European Patent Office (EPO) | A4 | |
| US2006105993A1 | United States of America | A1 | |
| BRPI0410306A | Brazil | A | |
| EP1556033A4 | European Patent Office (EPO) | A4 | |
| EP1567154A4 | European Patent Office (EPO) | A4 | |
| MXPA06001994A | Mexico | A | |
| ZA200409388B | South Africa | B | |
| NO20061528L | Norway | L |
Showing 100 of 539
Numbers
- Publication, EPODOC
- IS8340
- Application
- 8340
- Application, DOCDB
- 8340
- Application, EPODOC
- IS20060008340
Titles2
- Icelandic
- Fjölbreyttar myndir 3-(4-amínó-1-oxó-1,3 díhýdró-ísóindol-2-ýl)-piperidín-2,6-díons
- English
- Diverse Figures 3- (4-Amino-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidine-2,6-dione
Classification
- CPC, 14
- C07D401/04
- A61K31/445
- A61P25/04
- A61P27/02
- A61P29/00
- A61P35/00
- A61P35/02
- A61P37/00
- A61P37/02
- A61P37/06
- A61P7/00
- A61P9/00
- C07B2200/13
- B65D51/2864
- IPC, 4
- A61K
- A61K31 445
- A61K31 454
- C07D401 04